Details

Hits: 13048

Current role of transtympanic gentamicin therapy in the management of unilateral meniere’s disease
K. K. Desarda1, D. A. Bhisegaonkar 2
Abstract: Transtympanic gentamicin infusion is an alternative to surgical labyrinthectomy and Vestibular nerve section for the treatment of refractory vertigo associated with Meniere’s Gentamicin, the current drug of choice provides excellent vertigo control and is a less Invasive method to destroy the vestibular labyrinth. The goal of the treatment is to Eliminate the abnormal vestibular inputs from the vestibular inputs from the diseased ear Without adversely affecting the hearing. It’s salutary effect results from the damage of Both the sensory neuroepithelium and the dark cells of the labyrinth. Intratympanic Gentamicin may cause s. n. hearing loss In some patients {10–15%}. Despite this s. n. Loss, results are encouraging. 50 cases of unilateral Meniere’s disease were treated at KEM hospital, Pune, during 1996 to 2002 with the follow–up of 2 to 4 yrs. All cases were infused with gentamicin transtympanically for 4 to 6 weeks. N weekly basis with other surgical treatments are obviated by this treatment. This prospective study of gentamicin infusion revealed high success rate of controlling vertigo in about 92% patients. This treatment modality offers a less invasive but effective option for treating refractory vertigo of Meniere’s disease.

Read more: Transtympanic Gentamicin Therapy